Oral SCC is the most important diagnosis not to miss in mouth ulcer presentations — it is responsible for approximately 3,000 deaths per year in the UK, and survival is strongly stage-dependent: 5-year survival for stage I is approximately 80%, dropping to approximately 30% for stage IV. The GP should apply a strict 3-week rule: any oral ulcer that has not healed within 3 weeks must be referred on the 2WW head and neck pathway, regardless of whether it appears clinically benign. The risk factors most commonly associated with oral SCC in the UK: tobacco smoking (4-8x increased risk), heavy alcohol use (4-7x increased risk), and the combination of both (up to 30-40x increased risk). Human papillomavirus (HPV, especially HPV-16) is an increasingly important risk factor for oropharyngeal SCC (tonsil, base of tongue) in non-smokers — accounting for approximately 70-80% of new oropharyngeal cancers in the UK. GPs who reassure a patient with a floor-of-mouth ulcer with 'it's probably aphthous' and prescribe Adcortyl in Orabase without arranging follow-up are at risk of a delayed diagnosis medicolegal claim.

Leukoplakia is the most important oral white lesion to recognise and refer — it is defined as a white patch or plaque on the oral mucosa that cannot be wiped off and cannot be attributed to any other condition. It is a clinical diagnosis of exclusion: all other causes of oral white lesions must be excluded first (candidiasis, trauma, frictional keratosis, lichen planus, hairy leukoplakia). The malignant transformation rate of leukoplakia to SCC varies from 1% to 17% depending on the histological grade of dysplasia, the clinical pattern (homogeneous, speckled, or verrucous), and the anatomical site (floor of mouth and lateral tongue have highest risk). All leukoplakia requires 2WW referral for biopsy (to determine dysplasia grade) and specialist management. Speckled leukoplakia (erythroleukoplakia — red and white areas mixed) has the highest malignant transformation risk and requires particularly urgent referral. GPs should not treat leukoplakia empirically with topical antifungals without first confirming it is not fixed white — doing so delays diagnosis.

The bimanual palpation of the floor of the mouth is a clinical examination technique that GPs should be competent in for detecting submandibular masses, salivary gland pathology, and floor of mouth SCC — the technique: with one finger of the examining hand inside the patient's mouth on the floor of the mouth (between the tongue and the lower front teeth), the other hand is placed externally under the chin in the submandibular region. The two hands gently compress toward each other, allowing palpation of: the submandibular gland (to detect stones or masses), the floor of mouth tissue (for induration suggesting SCC), and the tongue base. The floor of the mouth is the second most common site for oral SCC (after the lateral and ventral tongue) and is an area that is easily missed on inspection alone due to tongue obstruction — bimanual palpation identifies submucosal masses that are not visible on surface examination. Any induration (firmness beyond normal tissue) in the floor of mouth should prompt immediate 2WW referral.

Burning mouth syndrome (BMS) management with topical clonazepam is an evidence-based approach that avoids the systemic side effects of oral benzodiazepines — the technique described in multiple RCTs involves dissolving a 0.5-1 mg clonazepam tablet in the mouth and holding it there for 1-3 minutes to allow topical mucosal absorption, then spitting it out. This achieves therapeutic concentrations at the oral mucosa while minimising systemic absorption (and therefore minimising sedation and dependence risk). Randomised controlled trials show topical clonazepam reduces BMS pain by approximately 50-60% in approximately 70% of patients. The mechanism is thought to involve GABA-A receptor modulation at peripheral nerve endings in the oral mucosa. Important caveats: if the patient swallows the dissolved tablet, systemic exposure occurs; patients should be warned about this and advised to spit. The IOCB (International Organisation for BMS) and IASP (International Association for the Study of Pain) guidelines support this approach as a first-line pharmacological treatment for BMS.

The 2WW head and neck cancer referral threshold for oral lesions is one of the most frequently missed in UK primary care — NICE NG12 (Suspected Cancer) specifies that an unexplained oral ulcer persisting for more than 3 weeks, or a suspicious oral lesion (white patch, red patch, or indurated area), in a patient over 45 (lower threshold because oral SCC is very rare under 45 but not impossible) should be referred on the 2WW pathway. The most important single factor driving missed oral SCC diagnoses in primary care: GP unfamiliarity with the presentation of early oral SCC (which is often painless, non-bleeding, and overlooked by both patient and clinician) combined with inadequate systematic oral examination. A GP who does not lift the tongue and inspect the lateral and ventral tongue surfaces, and the floor of the mouth, at a consultation for 'sore mouth' has not performed an adequate oral examination. The mouth examination takes 60 seconds with a good light and tongue depressor — and it is the most important 60 seconds in any oral symptoms consultation.

The ICS (inhaled corticosteroid) candida prevention strategy of mouth-rinsing after every dose is one of the most impactful, simple, and frequently not-communicated medication counselling points in respiratory medicine — inhaled corticosteroid particles deposit in the oropharynx and cause local immunosuppression of the mucosal immune response, allowing Candida albicans (which is commensal in the oropharynx in approximately 30-50% of people) to overgrow. The solution is mechanical removal of the ICS particles before they can cause local immunosuppression: rinsing the mouth and gargling with water and spitting immediately after each ICS dose. This single measure reduces the risk of ICS-induced oral candidiasis from approximately 30-40% to approximately 5%. Using a spacer device with MDI inhalers also reduces oropharyngeal deposition by approximately 90%. GPs prescribing ICS for the first time should make ICS mouth-rinsing advice part of the standard counselling at first prescription — it takes 30 seconds to demonstrate and significantly reduces candida-related morbidity.

MRONJ (medication-related osteonecrosis of the jaw) is an increasingly important iatrogenic condition in primary care given the widespread use of bisphosphonates for osteoporosis and bone metastases — GPs who prescribe alendronate (oral bisphosphonate) or refer for zoledronate (IV bisphosphonate) infusions should be aware that dental extraction and other dental procedures are major risk factors for MRONJ. The practical primary care intervention: before starting any bisphosphonate or denosumab, all patients should be referred for a dental assessment and any necessary dental treatment (extractions, periodontal treatment) should be completed while the patient is not yet on bisphosphonate therapy. The rationale: the risk of MRONJ from dental extraction in a patient who has been on an oral bisphosphonate for 3 years is approximately 0.5-0.7% (much lower for oral than IV bisphosphonates), but this risk is significantly reduced if the extraction is performed before bisphosphonate initiation. GPs should include 'dental review before commencing' in the counselling at any bisphosphonate or denosumab prescription — and document it.

The SLS-free toothpaste advice for recurrent aphthous ulcers is a simple, evidence-based intervention that is rarely communicated in primary care consultations — sodium lauryl sulphate (SLS) is a synthetic surfactant used in most commercially available toothpastes as a foaming agent. SLS disrupts the oral mucosal protective barrier by denaturing mucosal proteins, increasing mucosal permeability and sensitising the epithelium to irritants. Multiple clinical studies show that SLS-free toothpaste reduces aphthous ulcer frequency by approximately 60-70% in patients with recurrent aphthous stomatitis. Given that SLS-free toothpastes are widely available (Sensodyne Pronamel, Biotene, Tom's of Maine fluoride, Kingfisher) and inexpensive, this is a zero-risk, low-cost intervention that should be recommended to any patient with recurrent aphthous ulcers before or alongside topical triamcinolone prescription.

The medicolegal documentation standard for oral ulcer management requires a written record of the clinical findings, the decision-making rationale, and the safety-netting plan — a GP who sees a patient with a floor-of-mouth ulcer and documents only 'oral ulcer — prescribed Adcortyl in Orabase' without documenting the size, duration, character, whether it was indurated, the patient's smoking and alcohol history, and whether 2WW was considered, has an inadequate clinical record. The appropriate documentation: 'Oral ulcer lateral tongue, 8 mm, duration 10 days, non-indurated, regular borders, no associated lymphadenopathy. Patient is a non-smoker with minimal alcohol use. Clinical appearance consistent with aphthous ulcer. Topical triamcinolone prescribed. Safety-net: if not healed within 3 weeks, urgent review for 2WW referral. Patient advised to re-attend if not healed by [date].' This documents the clinical reasoning and the planned safety-net, providing a defensible record if the lesion later proves to be malignant.